Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: N-acetyl cysteine (NAC) is a glutathione precursor that has been shown to have antidepressant efficacy in a placebo-controlled trial. The current study aimed to investigate the maintenance effects of NAC following eight weeks of open-label treatment for bipolar disorder. METHOD: The efficacy of a double blind randomized placebo controlled trial of 2 g/day NAC as adjunct maintenance treatment for bipolar disorder was examined. Participants (n = 149) had a Montgomery Asberg Depression Rating Score of ≥12 at trial entry and, after eight weeks of open-label NAC treatment, were randomized to adjunctive NAC or placebo, in addition to treatment as usual. Participants (primarily outpatients) were recruited through public and private services and through newspaper advertisements. Time to intervention for a mood episode was the primary endpoint of the study, and changes in mood symptoms, functionality and quality of life measures were secondary outcomes. RESULTS: There was a substantial decrease in symptoms during the eight-week open-label NAC treatment phase. During the subsequent double-blind phase, there was minimal further change in outcome measures with scores remaining low. Consequently, from this low plateau, between-group differences did not emerge on recurrence, clinical functioning or quality of life measures. CONCLUSIONS: There were no significant between-group differences in recurrence or symptomatic outcomes during the maintenance phase of the trial; however, these findings may be confounded by limitations. TRIAL REGISTRATION: The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12607000074493).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 1×
“The participants were assessed at the commencement of the open-label phase using the Mini International Neuropsychiatric Interview Plus (MINI-Plus) [15].”
MethodGueorguieva, R., & Krystal, J. H. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.3.310 · Cited by 1,529
Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178
Self-citationGawryluk, J. W., Wang, J.-F., Andreazza, A. C., Shao, L., & Young, L. T. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000805 · Cited by 594 · cited 1×
“Given the limitations of these agents, polypharmacy is the routine rather than the exception [5] and most have significant tolerability issues that require routine safety monitoring [6].”
BackgroundBerk, M., Copolov, D. L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Bush, A. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.022 · Cited by 500
Self-citationFarr, S. A., Poon, H. F., Dogrukol‐Ak, D., Drake, J., Banks, W. A., Eyerman, E., Butterfield, D. A., & Morley, J. E. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01580.x · Cited by 459 · cited 1×
“In addition, benefits of NAC in other psychiatric disorders, including a large clinical trial of schizophrenia [8], and small scale clinical papers in obsessive-compulsive disorder [33] and compulsive disorders [9,33,34], pathological gambling [35] and cocaine dependence [36] have been reported.”
BackgroundN -acetylcysteine for antioxidant therapy: pharmacology and clinical utility
Dodd, S., Dean, O., Copolov, D. L., Malhi, G. S., & Berk, M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14728220802517901 · Cited by 413
Self-citationGlutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients
Lavoie, S., Murray, M. M., Deppen, P., Knyazeva, M. G., Berk, M., Boulat, O., Bovet, P., Bush, A. I., Conus, P., Copolov, D., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301624 · Cited by 371
Self-citationBerk, M., Dean, O., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B. S., Kohlmann, K., Jeavons, S., Hewitt, K., Allwang, C., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.06.005 · Cited by 181 · cited 2×
“NAC provides L-cysteine, the rate limiting factor in glutathione synthesis, and thereby increases central and peripheral glutathione [10].”
BackgroundMethodSelf-citationWeisler, R. H., Nolen, W. A., Neijber, A., Hellqvist, Å., Paulsson, B., & Trial 144 Study Investigators (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m06878 · Cited by 169
Research works printed but not linked: 28
- Malhi GS, Adams D, Berk M: Is lithium in a class of its own? A brief profile of its clinical use. Aust N Z J Psychiatry. 2009, 43: 1096-1104. 10.3109/00048670903279937. · DOI · Paper page
- Ng F, Hallam K, Lucas N, Berk M: The role of lamotrigine in the management of bipolar disorder. Neuropsychiatr Dis Treat. 2007, 3: 463-474.
- Malhi GS, Berk M, Bourin M, Ivanovski B, Dodd S, Lagopoulos J, Mitchell PB: A typical mood stabilizers: a "typical role for atypical antipsychotics. Acta Psychiatr Scand Suppl. 2005, 29-38. 426 · DOI
- Efrati S, Averbukh M, Berman S, Feldman L, Dishy V, Kachko L, Weissgarten J, Golik A, Averbukh Z: N-Acetylcysteine ameliorates lithium-induced renal failure in rats. Nephrol Dial Transplant. 2005, 20: 65-70. 10.1093/ndt/gfh573. · DOI
- Dean O, Bush AI, Berk M, Copolov DL, van den Buuse M: Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice. Behav Brain Res. 2009, 198: 258-262. 10.1016/j.bbr.2008.11.017. · DOI · Paper page
- Dean OM, van den Buuse M, Berk M, Copolov DL, Mavros C, Bush AI: N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder. Neurosci Lett. 2011, 499: 149-153. 10.1016/j.neulet.2011.05.027. · DOI · Paper page
- Dean O, Giorlando F, Berk M: N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011, 36: 78-86. · DOI · Paper page
- Das I, Khan NS, Puri BK, Sooranna SR, de Belleroche J, Hirsch SR: Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem Biophys Res Commun. 1995, 212: 375-380. 10.1006/bbrc.1995.1980. · DOI
- Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979, 134: 382-389. 10.1192/bjp.134.4.382. · DOI · Paper page
- Berk M, Malhi GS, Cahill C, Carman AC, Hadzi-Pavlovic D, Hawkins MT, Tohen M, Mitchell PB: The Bipolar Depression Rating Scale (BDRS): its development, validation and utility. Bipolar Disord. 2007, 9: 571-579. 10.1111/j.1399-5618.2007.00536.x. · DOI
- Guy W: ECDEU Assessment Manual for Psychopharmacology. 1976, Rockville, MD: U.S. Department of Health
- Bernardo M, Dodd S, Gama CS, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI, Berk M: Effects of N-acetylcysteine on substance use in bipolar disorder: a randomized placebo controlled clinical trial. Acta Neuropsychiatrica. 2009, 21: 239-245. 10.1111/j.1601-5215.2009.00415.x. · DOI
- Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997, 73: 159-171. 10.1016/S0165-1781(97)00123-6. · DOI · Paper page
- Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised. 1976, Washington DC: US Department of Health, Education, and Welfare, 76-338.
- American Psychiatric Association: DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 2000, Washington D.C.: American Psychiatric Association, 4
- Goldman HH, Skodol AE, Lave TR: Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry. 1992, 149: 1148-1156. · DOI · Paper page
- Keller MB, Lavori PW, Friedman B, Nielsen E, Endicott J, McDonald-Scott P, Andreasen NC: The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry. 1987, 44: 540-548. 10.1001/archpsyc.1987.01800180050009. · DOI · Paper page
- Leon AC, Solomon DA, Mueller TI, Turvey CL, Endicott J, Keller MB: The Range of Impaired Functioning Tool (LIFE-RIFT): a brief measure of functional impairment. Psychol Med. 1999, 29: 869-878. 10.1017/S0033291799008570. · DOI · Paper page
- Endicott J, Nee J, Harrison W, Blumenthal R: Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993, 29: 321-326.
- International conference on harmonisation: guidance on statistical principles for clinical trials (ICH-E9). 1997, {AU Query: Please provide the name and place of the publisher.}
- Mallinckrodt C, Watkin J, Molenberghs G, Carroll R: Choice of the primary analysis in longitudinal clinical trials. Pharmaceut Statist. 2004, 3: 161-169. 10.1002/pst.124. · DOI · Paper page
- Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M: N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. J Affect Disord. 2011, 129: 317-320. 10.1016/j.jad.2010.08.001. · DOI · Paper page
- Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G, Krystal JH, Coric V: N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl). 2006, 184: 254-256. 10.1007/s00213-005-0246-6. · DOI · Paper page
- Grant JE, Kim SW, Odlaug BL: N-Acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007, 62: 652-657. 10.1016/j.biopsych.2006.11.021. · DOI · Paper page
- Qian HR, Yang Y: Neuron differentiation and neuritogenesis stimulated by N-acetylcysteine (NAC). Acta Pharmacol Sin. 2009, 30: 907-912. 10.1038/aps.2009.72. · DOI · Paper page
- Ferreira FR, Biojone C, Joca SR, Guimaraes FS: Antidepressant-like effects of N-acetyl-L-cysteine in rats. Behav Pharmacol. 2008, 19: 747-750. 10.1097/FBP.0b013e3283123c98. · DOI · Paper page
- Xiong Y, Peterson PL, Lee CP: Effect of N-acetylcysteine on mitochondrial function following traumatic brain injury in rats. J Neurotrauma. 1999, 16: 1067-1082. 10.1089/neu.1999.16.1067. · DOI · Paper page
- Kato T, Kapczinski F, Berk M: Mitochondrial dysfunction and oxidative stress. Bipolar Disorder: Clinical and Neurobiological Foundations. Edited by: Yatham LN, Maj M. 2010, John Wiley & Sons Ltd, London, UK, 244-254. · DOI
Cited by
Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
Deepmala, Slattery, J., Kumar, N., Delhey, L., Berk, M., Dean, O., Spielholz, C., & Frye, R. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.04.015 · Cited by 463
Self-citationCognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies
Solé, B., Jiménez, E., Torrent, C., Reinares, M., Bonnin, C. D. M., Torres, I., Varo, C., Grande, I., Valls, E., Salagre, E., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx032 · Cited by 299
“Results from a large, randomized, double-blind controlled trial showed that N-acetyl cysteine (NAC) as an add-on treatment in patients with BD failed to find benefits in cognitive functioning (Berk et al., 2008, 2012; Dean et al., 2012).”
BackgroundRaghu, G., Berk, M., Campochiaro, P. A., Jaeschke, H., Marenzi, G., Richeldi, L., Wen, F.-Q., Nicoletti, F., & Calverley, P. M. A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666201230144109 · Cited by 280
Self-citationRosenblat, J., & McIntyre, R. (2017) · Brain Sciences · doi:10.3390/brainsci7110144 · Cited by 258
Rosenblat, J. D., Kakar, R., Berk, M., Kessing, L. V., Vinberg, M., Baune, B. T., Mansur, R. B., Brietzke, E., Goldstein, B. I., & McIntyre, R. S. (2016) · Bipolar Disorders · doi:10.1111/bdi.12373 · Cited by 199
Self-citation
Metadata
- Authors
- Berk, M., Dean, O. M., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B., Kohlmann, K., Jeavons, S., Hewitt, K., Moss, K., Allwang, C., Schapkaitz, I., Cobb, H., Bush, A. I., Dodd, S., & Malhi, G. S.
- Venue
- BMC Medicine
- Published
- 2012-08-14
- Volume
- 10
- Issue
- 1
- Pages
- 91-91
- ISSN
- 1741-7015 (ISSN-L)
- OpenAlex
- W2105920925
- Cited by
- 96
- References
- 10
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. https://app.cochat.ai/papers/10.1186/1741-7015-10-91
- The paper
- Berk, M., Dean, O. M., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B., Kohlmann, K., Jeavons, S., Hewitt, K., Moss, K., Allwang, C., Schapkaitz, I., Cobb, H., Bush, A. I., Dodd, S., & Malhi, G. S. (2012). Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. BMC Medicine. https://doi.org/10.1186/1741-7015-10-91
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.